Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

Executive Summary

• MarvelBiosciencesCorp. announced the acceptance of its Australian patent application (2021235803) for its lead drug candidate MB-204, with expected grant after August 28, 2026.
• The company highlighted robust preclinical data demonstrating MB-204 significantly outperformed the approved therapy trofinetide in Rett syndrome models, supporting its planned advancement into Phase I clinical trials.
• Recent milestones include securing U.S. and Japanese composition-of-matter patents for MB-204, selecting Novotech as a CRO for Phase I, obtaining non-dilutive funding from Alberta Innovates, and securing strategic investment from 5 Horizons Ventures.

Key Details

• Australian patent application 2021235803 for MB-204 was accepted on May 7, 2026, and is expected to be granted shortly after August 28, 2026.
• MB-204 is a novel fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline, currently in preclinical development for autism spectrum disorder, Rett syndrome, Fragile X syndrome, and depression.
• Preclinical studies in Rett syndrome models showed MB-204 significantly outperformed trofinetide across multiple efficacy endpoints, with sustained therapeutic benefits persisting after treatment cessation, suggesting potential disease-modifying effects.
• The compound has completed pre-clinical toxicology testing and demonstrated excellent pharmacokinetics and efficacy in depression and multiple autism models; it is currently being tested in Fragile X models.
• 2026 achievements include: granting of U.S. and Japanese composition-of-matter patents for MB-204; selection of Novotech as the CRO for the planned Phase I clinical trial; securing non-dilutive funding from Alberta Innovates; strategic investment participation from 5 Horizons Ventures; and development of novel pediatric-friendly liquid formulations.
• The company is transitioning from a pre-clinical organization to a clinical-stage drug development company.

Notable Quotes

• “We are continuing to extend our composition of matter patent protection of MB-204 to all major markets”, commented Marvel CEO Rod Matheson “and we continue to look forward to receiving similar rulings for the other jurisdictions. We have also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of our patent estate.”